TG Therapeutics Falls 30 Percent As CEO Discloses Partial Clinical Hold On Blood Cancer Trials

The increase in TG Therapeutics stock price was due to solid volume, which meant more shares were traded than in a normal session. This contrasts with the loss of 57.3% over the month. In the last week, TG Therapeutics Inc. saw a significant drop in its share prices after an SEC filing revealed that the FDA had placed a partial clinical hold on its studies of the U2 combination for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma indications. Earnings estimate revisions or changes in consensus EPS estimates for a particular stock over time, are strong predictors of near-term share price movements.

The partial hold on the CLL study was due to the fact that it is a multicenter trial, and one of the sites had an issue with IRB approval. The hold on the NHL study was because of an issue with patient enrollment. The company also presented data from the Phase 1/2 study of COVID-19 in combination with ibrutinib in patients with relapsed or refractory CLL.